Write a 100-350 word essay about the enzyme human GNPTG. Provide information related to enzyme: i) function, ii) reaction pathways, ii) Location, and iv) diseases. In writing include these four subheadings

### Function
Human GNPTG, or N-acetylglucosamine-1-phosphotransferase gamma subunit, is an essential component of the enzyme complex responsible for targeting lysosomal enzymes. The GNPTG subunit works in conjunction with GNPTAB to catalyze the formation of mannose-6-phosphate (M6P) tags on lysosomal enzymes. These tags are crucial for directing the enzymes to lysosomes, where they are required for breaking down various biomolecules.

### Reaction Pathways
GNPTG is involved in the pathway responsible for the lysosomal targeting of enzymes. It helps GNPTAB in transferring N-acetylglucosamine-1-phosphate to mannose residues on N-linked oligosaccharides of lysosomal enzymes. This tagging is the first and critical step in the formation of M6P markers. These markers are recognized by M6P receptors in the Golgi apparatus, which then guide the enzymes to lysosomes. Without the proper function of GNPTG, the enzymes may not receive the correct tags, leading to their misrouting and the failure to reach the lysosomes.

### Location
GNPTG is localized in the Golgi apparatus, where it plays a role in the modification and sorting of proteins. The Golgi apparatus serves as the central hub for processing and directing proteins to their appropriate destinations within the cell. GNPTG's function in the Golgi is vital for ensuring that lysosomal enzymes are correctly tagged with M6P and sent to the lysosomes, where they perform essential degradative functions.

### Diseases
Mutations in the GNPTG gene are associated with mucolipidosis III gamma (ML III gamma), a lysosomal storage disorder. This condition results from the improper tagging of lysosomal enzymes due to defective GNPTG function, leading to the accumulation of undigested substrates in lysosomes. Symptoms of ML III gamma include skeletal abnormalities, joint stiffness, developmental delays, and cardiovascular problems. The disease is typically milder than mucolipidosis II, but it still significantly impacts the quality of life. Understanding GNPTG's role in enzyme targeting is essential for diagnosing and managing these genetic disorders.